Ausgabe 3/2014
Inhalt (23 Artikel)
NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants
Jae-Sik Shin, Seung-Woo Hong, Jai-Hee Moon, Jin-Sun Kim, Kyung-Ah Jung, Seung-Mi Kim, Dae-Hee Lee, InKi Kim, Seon-Joo Yoon, Chang-Gyu Lee, Eun-Kyoung Choi, Joo-Young Lee, Kyu-pyo Kim, Yong Sang Hong, Jae-Lyun Lee, Bongcheol Kim, Eun Kyung Choi, Jung Shin Lee, Dong-Hoon Jin, Tae Won Kim
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model
Chang Hoon Moon, Seung Ju Lee, Ho Yong Lee, Le Thi Kim Dung, Wha Ja Cho, HeeJeong Cha, Jeong Woo Park, Young Joo Min
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres
Doris Mangiaracina Benbrook, Baskar Nammalwar, Andrew Long, Hiroyuki Matsumoto, Anil Singh, Richard A. Bunce, K. Darrell Berlin
Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair
Suraj Radhamani, Christopher Bradley, Terri Meehan-Andrews, Saleh K. Ihmaid, Jasim Al-Rawi
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
D. S. Hong, R. Kurzrock, A. Naing, J. J. Wheler, G. S. Falchook, J. S. Schiffman, N. Faulkner, M. J. Pilat, J. O’Brien, P. LoRusso
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande, Chia-Chi Lin, Daniel C. Cho, Geoffrey I. Shapiro, Eunice L. Kwak, Michael H. Silverman, Yunlong Tseng, Min-Wen Kuo, Wendy B. Mach, Shu-Chi Hsu, Teresa Coleman, James Chih-Hsin Yang, Ann-Lii Cheng, Mohammad H. Ghalib, Imran Chuadhary, Sanjay Goel
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
E. M. Dunbar, B. S. Coats, A. L. Shroads, T. Langaee, A. Lew, J. R. Forder, J. J. Shuster, D. A. Wagner, P. W. Stacpoole
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies
Siqing Fu, Ming-Mo Hou, Jennifer Wheler, David Hong, Aung Naing, Apostolia Tsimberidou, Filip Janku, Ralph Zinner, Sarina Piha-Paul, Gerald Falchook, Macus Tien Kuo, Razelle Kurzrock
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer
Yoshito Komatsu, Takayuki Yoshino, Kentaro Yamazaki, Satoshi Yuki, Nozomu Machida, Takahide Sasaki, Ichinosuke Hyodo, Yutaka Yachi, Hiroshi Onuma, Atsushi Ohtsu
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
Lot A. Devriese, Kevin M. Koch, Marja Mergui-Roelvink, Gemma M. Matthys, Wen Wee Ma, Andre Robidoux, Joe J. Stephenson, Quincy S. C. Chu, Keith W. Orford, Leanne Cartee, Jeff Botbyl, Nikita Arya, Jan H. M. Schellens
Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
Kevin R. Kelly, Thomas C. Shea, André Goy, Jesus G. Berdeja, Craig B. Reeder, Kevin T. McDonagh, Xiaofei Zhou, Hadi Danaee, Hua Liu, Jeffrey A. Ecsedy, Huifeng Niu, Ely Benaim, Swaminathan Padmanabhan Iyer
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies
Francois Goldwasser, Sandrine Faivre, Jerome Alexandre, Cinthya Coronado, Eva M. Fernández-García, Carmen M. Kahatt, Pilar García Paramio, Jorge Luis Iglesias Dios, Bernardo Miguel-Lillo, Eric Raymond
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Carolyn D. Britten, Alex A. Adjei, Robert Millham, Brett E. Houk, Gary Borzillo, Kristen Pierce, Zev A. Wainberg, Patricia M. LoRusso
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
Margaret von Mehren, Carolyn D. Britten, Peter Pieslor, Wayne Saville, Artemios Vassos, Sarah Harris, Gerald R. Galluppi, Mohamed Darif, Zev A. Wainberg, Roger B. Cohen, Stephen Leong
Phase II trial of vorinostat in advanced melanoma
N. B. Haas, I. Quirt, S. Hotte, E. McWhirter, R. Polintan, S. Litwin, P. D. Adams, T. McBryan, L. Wang, L. P. Martin, M. vonMehren, R. K. Alpaugh, J. Zweibel, A. Oza
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab
Jeeyun Lee, Yong Sang Hong, Jung Yong Hong, Se Won Han, Tae Won Kim, Hye Jin Kang, Tae You Kim, Kyu-pyo Kim, Suk Hyung Kim, In-Gu Do, Kyoung-Mee Kim, Insuk Sohn, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Yong Beom Cho, Woo Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Young Suk Park, Won Ki Kang
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
Allyson J. Ocean, Paul Christos, Joseph A. Sparano, Manish A. Shah, Rhonda K. Yantiss, Jonathan Cheng, Juan Lin, Michael Papetti, Dan Matulich, Felice Schnoll-Sussman, Christen Besanceney-Webler, Jenny Xiang, Maureen Ward, Kaili Temple Dilts, Roger Keresztes, Shannon Holloway, Eric X. Chen, John J. Wright, Maureen E. Lane
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer
Alan L. Ho, Brynna L. Lipson, Eric J. Sherman, Han Xiao, Matthew G. Fury, Arlyn Apollo, Nagashree Seetharamu, Camelia S. Sima, Sofia Haque, John K. Lyo, Roberta Sales, Lisa Cox, David G. Pfister
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
A. Necchi, P. Giannatempo, L. Mariani, E. Farè, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchianò, N. Nicolai, M. Maffezzini, E. Togliardi, M. G. Daidone, A. M. Gianni, R. Salvioni, F. De Braud
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer
Jeeyun Lee, Sang Joon Shin, Ik Joo Chung, Tae Won Kim, Hoo-Geun Chun, Dong Bok Shin, Yeul Hong Kim, Hong Suk Song, Sae-Won Han, Jong Gwang Kim, Sun Young Kim, Young Jin Choi, Hyun Cheol Chung
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer
Audrey Bellesoeur, Edith Carton, Olivier Mir, Lionel Groussin, Benoit Blanchet, Bertrand Billemont, Jérôme Clerc, François Goldwasser
Successful readministration of trastuzumab after severe immune reactions in two breast cancer patients
R. Tanz, N. Meillan, N. Libert, N. Magne, L. Vedrine, C. Chargari
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Carolyn D. Britten, Alex A. Adjei, Robert Millham, Brett E. Houk, Gary Borzillo, Kristen Pierce, Zev A. Wainberg, Patricia M. LoRusso